Bone marrow obesity as a component of the pathogenesis of osteoporosis and its pharmacokinetic treatment with resveratrol
https://doi.org/10.21626/vestnik/2025-2/09
EDN: WBRKKX
Abstract
Objective - to investigate changes in the fatty tissue of the bone marrow of the proximal halves of the femur and tibia in experimental postmenopausal osteoporosis and its therapy with resveratrol.
Materials and methods. The study was performed on 15 female Wistar rats. A model of postmenopausal osteoporosis was created by bilateral ovariectomy with a follow-up period of 56 days. Resveratrol therapy in the experimental group was performed by daily intraperitoneal administration at a dose of 2 mg/ kg during the same follow-up period. Histological examination with computer analysis of images and morphometry, absorption X-ray densitometry were performed.
Results. Bilateral ovariectomy in experimental Wistar rat animals 8 weeks after ovariectomy, together with osteoporotic lesion, leads to an increase in the volume of bone marrow adipose tissue with hyperplastic type of obesity in the femur and mixed in tibia. Resveratrol at a dose of 2 mg / kg, without affecting the diameter of adipocytes, significantly reduces their number, reducing the degree of bone marrow obesity.
Conclusion. Resveratrol at a dose of 2 mg/kg has a pronounced pharmacological effect on the fatty component of the femoral and tibial bone marrow in the Wistar rat model of postmenopausal osteoporosis, reducing the degree of bone marrow obesity. This may reflect its effect on the fixation of bone marrow stromal precursors with a switch mainly to the osteoblastic direction of differentiation, which explains its osteoprotective and regenerative effects.
About the Authors
Olga A. Shevchenko
Belgorod State National Research University (NRU "BelSU")
Russian Federation
Russian Federation
Alexander A. Dolzhikov
Belgorod State National Research University (NRU "BelSU")
Russian Federation
Russian Federation
References
1. Rozhinskaya L.Y., Lutsenko A.S. Report on the international symposium on osteoporosis. Osteoporosis and Bone Diseases. 2021;24(3);33-34 (in Russ). EDN: GTXKDU.
2. Clinical recommendations “Osteoporosis” 2021; 82 p. (in Russ). URL: https://cr.minzdrav.gov.ru/recomend/87_4
3. Gkastaris K., Goulis D.G., Potoupnis M., Anastasilakis A.D., Kapetanos G. Obesity, osteoporosis and bone metabolism. J Musculoskelet Neuronal Interact. 2020;20(3):372-381.
4. Arjunan D., Prasad T.N., Das L., Bhadada S.K. Osteoporosis and Obesity. Indian J Orthop. 2023;57(Suppl 1):218-224. DOI: 10.1007/s43465-023-01052-9.
5. Kim T.Y., Schafer A.L. Diabetes and Bone Marrow Adiposity. Curr Osteoporos Rep. 2016;14(6):337-344. DOI: 10.1007/s11914-016-0336-x.
6. Martiniakova M., Biro R., Penzes N., Sarocka A., Kovacova V., Mondockova V., Omelka R. Links among Obesity, Type 2 Diabetes Mellitus, and Osteoporosis: Bone as a Target.Int J Mol Sci. 2024;25(9):4827. DOI: 10.3390/ijms25094827.
7. Brailova N.V., Kuznetsova V.A., Dudinskaya E.N., Tkacheva O.N. Aging bone.Russian journal of geriatric medicine. 2020;(2):147-153 (in Russ). DOI: 10.37586/2686-8636-2-2020-147-153. EDN: UDAFYN.
8. Infante A., Rodríguez C.I. Osteogenesis and aging: lessons from mesenchymal stem cells. Stem Cell Res Ther. 2018;9(1):244. DOI: 10.1186/s13287-018-0995-x.
9. Yousefzadeh N., Kashfi K., Jeddi S., Ghasemi A. Ovariectomized rat model of osteoporosis: a practical guide. EXCLI J. 2020;19:89-107. DOI: 10.17179/excli2019-1990.
10. Dolzhikov A.A., Shevchenko O.A. Stimulation of proliferation and osteoblastic differentiation of osteogenic precursors as pharmacological effects of resveratrol in hypoestrogenism-induced osteoporosis: structural and functional manifestations and possible mechanisms. Humans and their health. 2024;27(3):109-118 (in Russ.). DOI: 10.21626/vestnik/2024-3/11. EDN: XMAUWW.
11. Dolzhikov A.A., Shevchenko O.A., Dolzhikova I.N. Dynamics of structural and functional changes in the proximal epiphysis of the femur in experimental postmenopausal osteoporosis and resveratrol therapy. Modern Science. 2024; (7-1):42-50 (in Russ.). EDN: MMYALY.
12. Stenderup K., Justesen J., Clausen C., Kassem M. Aging is associated with decreased maximal life span and accelerated senescence of bone marrow stromal cells. Bone. 2003;33(6):919-926. DOI: 10.1016/j.bone.2003.07.005.
13. Shishkova V.N., Shishkova V.N. Obesity and osteoporosis. Osteoporosis and Bone Diseases. 2011;14(1):21-26 (in Russ). DOI: 10.14341/osteo2011121-26.
14. Akune T., Ohba S., Kamekura S., Yamaguchi M., Chung U.I., Kubota N., Terauchi Y., Harada Y., et al. PPARgamma insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J Clin Invest. 2004;113(6):846-855. DOI: 10.1172/JCI19900.
15. Schrauwen P., Timmers S. Can resveratrol help to maintain metabolic health? Proc Nutr Soc. 2014;73(2):271-277. DOI: 10.1017/S0029665113003856.
16. Trunov K.S., Danilenko A.P., Gudyrev O.S., Danilenko L.M., Pokrovsky M.V., Skachilova S.Ya., Cherednichenko A.A, et al. Supramolecular complex based on 3-hydroxypyridine derivatives prevents osteoporosis caused by estrogen deficiency by inhibiting oxidative stress. Experimental and clinical pharmacology. 2023;86(2):28-35 (in Russ). DOI: 10.30906/0869-2092-2023-86-2-28-35. EDN:JGCGCN.
17. Moon D.K., Kim B.G., Lee A.R., In Choe Y., Khan I., Moon K.M., Jeon R.H., Byun J.H., et al. Resveratrol can enhance osteogenic differentiation and mitochondrial biogenesis from human periosteum-derived mesenchymal stem cells. J Orthop Surg Res. 2020;15(1):203. DOI: 10.1186/s13018-020-01684-9.
18. López-Otín C., Blasco M.A., Partridge L., Serrano M., Kroemer G. The hallmarks of aging. Cell. 2013;153(6):1194-217. DOI: 10.1016/j.cell.2013.05.039.
19. Baile C.A., Yang J.Y., Rayalam S., Hartzell D.L., Lai C.Y., Andersen C., Della-Fera M.A. Effect of resveratrol on fat mobilization. Ann N Y Acad Sci. 2011;1215:40-7. DOI: 10.1111/j.1749-6632.2010.05845.x.
20. Feng J., Liu S., Ma S., Zhao J., Zhang W., Qi W., Cao P., Wang Z., et al. Protective effects of resveratrol on postmenopausal osteoporosis: regulation of SIRT1-NF-κB signaling pathway. Acta Biochim Biophys Sin (Shanghai). 2014;46(12):1024-1233. DOI: 10.1093/abbs/gmu103.
21. Pukhalskaia A.E., Kvetnoy I.M., Linkova N.S., Diatlova A.S., Gutop E.O., Kozlov K.L., Paltsev M.A. Sirtuins and aging. Progress in physiological science. 2022;53(1):16-27 (in Russ). DOI: 10.31857/S0301179821040056. EDN: KUNLXB.
Review
For citations:
Shevchenko O.A., Dolzhikov A.A. Bone marrow obesity as a component of the pathogenesis of osteoporosis and its pharmacokinetic treatment with resveratrol. Humans and their health. 2025;28(2):72-79. (In Russ.) https://doi.org/10.21626/vestnik/2025-2/09. EDN: WBRKKX
Views:
46
Email this article 